臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 2823024
	???header.visitor??? : 30265646 ???header.onlineuser??? : 1038 ???header.sponsordeclaration???

???search.scope???

???search.advance???

???search.login???

???search.administrator???

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"krissel h"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2022-08-19T00:20:47Z	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma	Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y.
臺大學術典藏	2021-01-26T03:36:43Z	Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study	Zhou T.; Zhou F.; Guo J.; Shi H.; Yao X.; Guo H.; Yuan J.; Tian Y.; Zhang X.; Wang S.; Jiang Y.; Zou Q.; Zhou D.; Li H.; Li F.; Lee J.L.; CHUNG-HSIN CHEN; Park S.H.; Ng Q.S.; Ma J.; Zheng R.; Ding Q.; Liu X.; Li R.; Krissel H.; Wagner V.J.; Sun Y.
臺大學術典藏	2020-04-10T12:51:06Z	A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma	Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y.
國立成功大學	2018	Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma	Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M.

Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page